Literature DB >> 14976257

P2X7 receptors control 2-arachidonoylglycerol production by microglial cells.

Anke Witting1, Lisa Walter, Jennifer Wacker, Thomas Möller, Nephi Stella.   

Abstract

Endogenous cannabinoid ligands (endocannabinoids) produced by neurons, astrocytes, and microglial cells activate cannabinoid receptors, the molecular target for marijuana's bioactive ingredient Delta(9)-tetrahydrocannabinol. The molecular mechanism underlying the production of the most abundant endocannabinoid, 2-arachidonoylglycerol (2-AG), is unclear. A prevalent hypothesis proposes that activation of metabotropic receptors coupled to the phosphatidylinositol-specific phospholipase C and diacylglycerol (DG) lipase pathway will systematically lead to increases in 2-AG production. Here, we show that ATP increases 2-AG production by cultured microglial cells in a phosphatidylinositol-specific phospholipase C and DG lipase-dependent manner. However, efficacious activation of metabotropic P2Y purinergic receptors coupled to phosphatidylinositol-specific phospholipase C does not increase 2-AG production. This suggests that ionotropic, and not metabotropic, purinergic receptors control 2-AG production at an unexpected enzymatic step of its metabolic pathway. We show that activation of P2X(7) ionotropic receptors, which are highly permeable to calcium, is necessary and sufficient to increase 2-AG production in microglial cells. We also show that the sustained rise in intracellular calcium induced by activation of P2X(7) receptors directly increases DG lipase activity while inhibiting the activity of monoacylglycerol lipase, the enzyme that degrades 2-AG. This inverse sensitivity of DG lipase and monoacylglycerol lipase to calcium constitutes an original and efficient modality for sustained accumulation of 2-AG. Because prolonged increases in 2-AG amounts in brain parenchyma are thought to orchestrate neuroinflammation, the enzymatic steps involved in 2-AG synthesis and degradation by microglial cells constitute appealing targets for therapy aimed at controlling exacerbated neuroinflammation.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 14976257      PMCID: PMC365769          DOI: 10.1073/pnas.0306707101

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  42 in total

1.  Extracellular ATP or ADP induce chemotaxis of cultured microglia through Gi/o-coupled P2Y receptors.

Authors:  S Honda; Y Sasaki; K Ohsawa; Y Imai; Y Nakamura; K Inoue; S Kohsaka
Journal:  J Neurosci       Date:  2001-03-15       Impact factor: 6.167

Review 2.  Microglia: activation and their significance in the central nervous system.

Authors:  K Nakajima; S Kohsaka
Journal:  J Biochem       Date:  2001-08       Impact factor: 3.387

Review 3.  Immune function of microglia.

Authors:  F Aloisi
Journal:  Glia       Date:  2001-11       Impact factor: 7.452

4.  Differential assembly of rat purinergic P2X7 receptor in immune cells of the brain and periphery.

Authors:  M Kim; V Spelta; J Sim; R A North; A Surprenant
Journal:  J Biol Chem       Date:  2001-04-19       Impact factor: 5.157

5.  Effects of cannabinoids on LPS-stimulated inflammatory mediator release from macrophages: involvement of eicosanoids.

Authors:  Y H Chang; S T Lee; W W Lin
Journal:  J Cell Biochem       Date:  2001       Impact factor: 4.429

Review 6.  Receptors for purines and pyrimidines.

Authors:  V Ralevic; G Burnstock
Journal:  Pharmacol Rev       Date:  1998-09       Impact factor: 25.468

Review 7.  Endocannabinoids: endogenous cannabinoid receptor ligands with neuromodulatory action.

Authors:  V Di Marzo; D Melck; T Bisogno; L De Petrocellis
Journal:  Trends Neurosci       Date:  1998-12       Impact factor: 13.837

8.  Inhibition of store-operated Ca(2+) influx by acidic extracellular pH in cultured human microglia.

Authors:  C Khoo; J Helm; H B Choi; S U Kim; J G McLarnon
Journal:  Glia       Date:  2001-10       Impact factor: 7.452

9.  An endogenous cannabinoid (2-AG) is neuroprotective after brain injury.

Authors:  D Panikashvili; C Simeonidou; S Ben-Shabat; L Hanus; A Breuer; R Mechoulam; E Shohami
Journal:  Nature       Date:  2001-10-04       Impact factor: 49.962

10.  Endocannabinoids control spasticity in a multiple sclerosis model.

Authors:  D Baker; G Pryce; J L Croxford; P Brown; R G Pertwee; A Makriyannis; A Khanolkar; L Layward; F Fezza; T Bisogno; V Di Marzo
Journal:  FASEB J       Date:  2000-12-08       Impact factor: 5.191

View more
  67 in total

1.  ATP-P2X7 receptor signaling controls basal and TNFα-stimulated glial cell proliferation.

Authors:  Jian Zou; Ryan P Vetreno; Fulton T Crews
Journal:  Glia       Date:  2012-02-01       Impact factor: 7.452

2.  The Central Role of Glia in Pathological Pain and the Potential of Targeting the Cannabinoid 2 Receptor for Pain Relief.

Authors:  Jenny L Wilkerson; Erin D Milligan
Journal:  ISRN Anesthesiol       Date:  2011

3.  Estrogen and P2 Purinergic Receptor Systems in Microglia: Therapeutic Targets for Neuroprotection.

Authors:  Jessica M Crain; Jyoti J Watters
Journal:  Open Drug Discov J       Date:  2010-01-01

4.  Purine receptor-mediated endocannabinoid production and retrograde synaptic signalling in the cerebellar cortex.

Authors:  Flora E Kovacs; Peter Illes; Bela Szabo
Journal:  Br J Pharmacol       Date:  2011-02       Impact factor: 8.739

Review 5.  Endocannabinoids in cerebrovascular regulation.

Authors:  Zoltán Benyó; Éva Ruisanchez; Miriam Leszl-Ishiguro; Péter Sándor; Pál Pacher
Journal:  Am J Physiol Heart Circ Physiol       Date:  2016-01-29       Impact factor: 4.733

Review 6.  Purinergic signaling and microglia.

Authors:  Katrin Färber; Helmut Kettenmann
Journal:  Pflugers Arch       Date:  2006-06-21       Impact factor: 3.657

7.  Multiple sclerosis may disrupt endocannabinoid brain protection mechanism.

Authors:  Esther Shohami; Raphael Mechoulam
Journal:  Proc Natl Acad Sci U S A       Date:  2006-04-10       Impact factor: 11.205

Review 8.  P2X7 receptors in oligodendrocytes: a novel target for neuroprotection.

Authors:  Carlos Matute
Journal:  Mol Neurobiol       Date:  2008-08-14       Impact factor: 5.590

9.  Diacylglycerol lipase β inhibition reverses nociceptive behaviour in mouse models of inflammatory and neuropathic pain.

Authors:  J L Wilkerson; S Ghosh; D Bagdas; B L Mason; M S Crowe; K L Hsu; L E Wise; S G Kinsey; M I Damaj; B F Cravatt; A H Lichtman
Journal:  Br J Pharmacol       Date:  2016-04-08       Impact factor: 8.739

10.  An optimized GC-MS method detects nanomolar amounts of anandamide in mouse brain.

Authors:  Giulio G Muccioli; Nephi Stella
Journal:  Anal Biochem       Date:  2007-09-29       Impact factor: 3.365

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.